Evidence map›Paper›PMID 41888739›Full record

ArticleBMC psychiatry2026

Assessing demographic and clinical characteristics and healthcare resource utilization of patients with schizophrenia with inadequate response to antipsychotic treatment.

Andre Hejazi, Morgan Bron, M Mercedes Perez-Rodriguez, Aida Attar, Maria Victoria Burgess, Erika Giraldo, Janelle Nimer, Joseph Biskupiak

Abstract read
In one paragraph

Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andre HejaziDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Morgan BronNeurocrine Biosciences, Inc., San Diego, CA, 92130, USA.
M Mercedes Perez-RodriguezDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Aida AttarNeurocrine Biosciences, Inc., San Diego, CA, 92130, USA.
Maria Victoria BurgessNeurocrine Biosciences, Inc., San Diego, CA, 92130, USA.
Erika GiraldoNeurocrine Biosciences, Inc., San Diego, CA, 92130, USA.
Janelle NimerDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. janelle@utahhealingcenter.org.
Joseph BiskupiakDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSchizophrenia is a severe mental illness with substantial health, social, and economic impacts. Despite the use of antipsychotics as the standard treatment, many patients fail to achieve an adequate response. This study examined differences in demographics, social determinants of health, treatment patterns, and healthcare resource utilization across antipsychotic response groups.

methodsThis retrospective cohort study used electronic health record (EHR) data from the University of Utah Health System (2017–2021). Patients aged 13 years or older with schizophrenia ICD codes and at least one prescribed antipsychotic were classified into adequate response (1 antipsychotic trial), inadequate response (2 antipsychotic trials), treatment-resistant schizophrenia (TRS), (TRS; 3 + antipsychotic trials or clozapine use), or nonadherent. As clozapine is the only antipsychotic approved for TRS management, TRS patients were categorized as clozapine-treated (TRS-C) or without clozapine (TRS-WC). Nonadherent patients were defined as having no providers documentation of taking antipsychotics as prescribed (outside of inpatient hospitalizations). Descriptive statistics and linear regression were used to compare social determinants of health and healthcare resource utilization, including inpatient (IP), outpatient (OP), and emergency department (ED) visits over a one-year follow-up period, and analyzed using linear regression to generate incidence rate ratios. Multivariable regression adjusted for potential confounders.

resultsAmong 408 patients (mean age 47 years; 72% male; 74% White), 29.9% had adequate response, 32.4% had inadequate response, 9.6% TRS-C, 13.0% TRS-WC, and 15.2% were nonadherent. Homelessness ranged from 8% in TRS-C to 73% in nonadherent patients (p < 0.001). Psychiatric IP visits were higher in inadequate response (IRR = 12.32), TRS-C (IRR = 8.86), and TRS-WC (IRR = 13.04) compared to adequate response (p < 0.001). Psychiatric ED visits were similarly elevated in inadequate response (IRR = 10.86, p < 0.001), TRS-C (incidence rate ratio = 5.47, p = 0.02), and TRS-WC (IRR = 13.81, p < 0.001) when compared to adequate response. Homelessness (IRR = 1.91, 95% CI [1.34–2.72] p < 0.001), Unemployment (IRR = 2.8, 95% CI [1.62–4.84] p < 0.001), and Social Security Disability Insurance (SSDI) enrollment (IRR = 1.83, 95% CI [1.29–2.58] p < 0.001) were all associated with increased all-cause IP visits. Medicare coverage was associated with decreased all-cause IP visits (IRR = 0.51, 95% CI [0.33–0.77] p = 0.002).

conclusionThis study identified significant associations between social and structural conditions (e.g., housing status, incarceration, insurance coverage, and social support) and healthcare resource utilization, alongside differences by demographic and clinical characteristics (e.g., age, comorbidities). Targeted interventions addressing homelessness, improving adherence, and optimizing care pathways are warranted for high-risk subgroups.

Indexed as

Antipsychotic AgentsPatient Acceptance of Health CareSchizophreniaSchizophrenia, Treatment-ResistantAdultClozapineEmergency Room VisitsFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultAntipsychotic AgentsClozapineAntipsychotic treatmentEarly interventionRecovery-oriented careRelapse preventionSchizophreniaSocial determinants of healthSocial functioningTreatment adherenceTreatment resistant

Identifiers

PMID41888739
PMCPMC13141273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.